Azitra to Participate in the 2024 Maxim Healthcare Virtual Summit
Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company specializing in precision dermatology, has been invited to present at the 2024 Maxim Healthcare Virtual Summit. The event, hosted by Maxim Group , will take place from October 15-17, 2024.
Azitra's Chief Operating Officer, Travis Whitfill, will participate in a panel presentation on Thursday, October 17, 2024, at 2:00 p.m. ET. The presentation will be part of the rare disease panel, featuring Azitra alongside other companies such as Quoin Pharmaceuticals, Rezolute, and Zevra Therapeutics.
The summit will showcase a range of biotechnology, diagnostic, medical device, and healthcare information technology companies. Maxim Senior Analysts will host interactive discussions with CEOs and key management, providing insights into various healthcare sectors.
Azitra, Inc. (NYSE American: AZTR), un'azienda biopharmaceuticala in fase clinica specializzata in dermatologia di precisione, è stata invitata a presentare al 2024 Maxim Healthcare Virtual Summit. L'evento, ospitato da Maxim Group, si svolgerà dal 15 al 17 ottobre 2024.
Il Chief Operating Officer di Azitra, Travis Whitfill, parteciperà a una presentazione di panel giovedì, 17 ottobre 2024, alle 14:00 ET. La presentazione farà parte del panel sulle malattie rare, con Azitra insieme ad altre aziende come Quoin Pharmaceuticals, Rezolute e Zevra Therapeutics.
Il summit presenterà una serie di aziende nei settori della biotecnologia, diagnostica, dispositivi medici e tecnologie informatiche per la salute. Gli analisti senior di Maxim condurranno discussioni interattive con CEO e key management, fornendo approfondimenti su vari settori della sanità.
Azitra, Inc. (NYSE American: AZTR), una empresa biofarmacéutica en etapa clínica especializada en dermatología de precisión, ha sido invitada a presentar en el 2024 Maxim Healthcare Virtual Summit. El evento, organizado por Maxim Group, se llevará a cabo del 15 al 17 de octubre de 2024.
El Director de Operaciones de Azitra, Travis Whitfill, participará en una presentación de panel el jueves 17 de octubre de 2024 a las 2:00 p.m. ET. La presentación formará parte del panel sobre enfermedades raras, presentando a Azitra junto a otras empresas como Quoin Pharmaceuticals, Rezolute y Zevra Therapeutics.
El summit mostrará una variedad de empresas en biotecnología, diagnóstico, dispositivos médicos y tecnología informática en salud. Los analistas senior de Maxim tendrán discusiones interactivas con CEOs y personal clave, proporcionando información sobre varios sectores de salud.
Azitra, Inc. (NYSE American: AZTR), 정밀 피부과를 전문으로 하는 임상 단계의 생명공학 회사가 2024 Maxim Healthcare Virtual Summit에 초청받았습니다. 이 행사는 Maxim Group이 주최하며 2024년 10월 15일부터 17일까지 진행됩니다.
Azitra의 최고 운영 책임자인 Travis Whitfill는 2024년 10월 17일 목요일 오후 2시(ET)에 패널 발표에 참여할 것입니다. 발표는 희귀 질병 패널의 일환으로, Azitra와 함께 Quoin Pharmaceuticals, Rezolute 및 Zevra Therapeutics와 같은 다른 회사들이 소개됩니다.
이번 서밋은 바이오테크놀로지, 진단, 의료 기기 및 헬스케어 정보 기술 분야의 다양한 기업들을 소개할 것입니다. Maxim의 수석 애널리스트들이 CEO 및 주요 경영진과 함께하는 인터랙티브 토론을 주최하여 다양한 헬스케어 분야에 대한 통찰력을 제공합니다.
Azitra, Inc. (NYSE American: AZTR), une entreprise biopharmaceutique en phase clinique spécialisée dans la dermatologie de précision, a été invitée à présenter au 2024 Maxim Healthcare Virtual Summit. L'événement, organisé par Maxim Group, se déroulera du 15 au 17 octobre 2024.
Le directeur des opérations d'Azitra, Travis Whitfill, participera à une présentation de panel le jeudi 17 octobre 2024 à 14h00 ET. La présentation fera partie du panel sur les maladies rares, avec Azitra aux côtés d'autres entreprises comme Quoin Pharmaceuticals, Rezolute et Zevra Therapeutics.
Le sommet mettra en avant une gamme d'entreprises dans les domaines de la biotechnologie, du diagnostic, des dispositifs médicaux et de la technologie de l'information en santé. Les analystes seniors de Maxim animeront des discussions interactives avec des PDG et des responsables clés, offrant des perspectives sur divers secteurs de la santé.
Azitra, Inc. (NYSE American: AZTR), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf präzise Dermatologie spezialisiert hat, wurde eingeladen, beim 2024 Maxim Healthcare Virtual Summit zu präsentieren. Die Veranstaltung, die von der Maxim Group ausgerichtet wird, findet vom 15. bis 17. Oktober 2024 statt.
Der Chief Operating Officer von Azitra, Travis Whitfill, wird an einer Panel-Präsentation am Donnerstag, den 17. Oktober 2024 um 14:00 Uhr ET teilnehmen. Die Präsentation ist Teil des Panels über seltene Krankheiten, in dem Azitra zusammen mit anderen Unternehmen wie Quoin Pharmaceuticals, Rezolute und Zevra Therapeutics vorgestellt wird.
Der Summit wird eine Reihe von Unternehmen aus den Bereichen Biotechnologie, Diagnostik, Medizintechnik und Gesundheitstechnologie präsentieren. Senior Analysten von Maxim werden interaktive Diskussionen mit CEOs und Schlüsselmanagern führen und Einblicke in verschiedene Gesundheitssektoren geben.
- None.
- None.
2024 Maxim Healthcare Virtual Summit – October 15-17, 2024
Format: Panel presentation
Date/Time: Thursday, October 17, 2024 at 2:00 p.m. ET
Participant: Travis Whitfill, Chief Operating Officer
Location: Virtual
Registration: Here
Maxim Senior Analysts will host a wide range of biotechnology, diagnostic, medical device, and healthcare information technology companies in a series of presentations and interactive discussions with CEOs and key management.
The presentation will be included in the rare disease panel on Thursday, October 17, 2024 at 2:00 p.m. ET. The companies present will include:
Azitra, Inc. (NYSEAM: AZTR)
Quoin Pharmaceuticals, Ltd. (NasdaqCM: QNRX)
Rezolute, Inc. (NasdaqCM: RZLT)
Zevra Therapeutics, Inc. (NasdaqCM: ZVRA)
About Maxim Group LLC
Maxim Group LLC is a full-service investment banking, securities and wealth management firm headquartered in
About Azitra, Inc.
Azitra, Inc. is an early-stage clinical biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. The Company has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for unique therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen the Company's library of strains for drug like molecules. The Company's initial focus is on the development of genetically engineered strains of Staphylococcus epidermidis, or S. epidermidis, which the Company considers to be an optimal therapeutic candidate species for engineering of dermatologic therapies. For more information, please visit https://azitrainc.com/.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Forward-looking statements are based on the Company’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in our Form 10-Q filed with the SEC on August 12, 2024. Azitra explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241014503518/en/
Norman Staskey
Chief Financial Officer
staskey@azitrainc.com
Source: Azitra, Inc.
FAQ
When is Azitra (AZTR) presenting at the 2024 Maxim Healthcare Virtual Summit?
Who will be representing Azitra (AZTR) at the 2024 Maxim Healthcare Virtual Summit?
What is the format of Azitra's (AZTR) participation in the 2024 Maxim Healthcare Virtual Summit?
Which other companies will be presenting alongside Azitra (AZTR) in the rare disease panel?
What is the date range for the 2024 Maxim Healthcare Virtual Summit featuring Azitra (AZTR)?
